Methods for Identifying Out-of-Trend Results in Ongoing Stability Data - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Methods for Identifying Out-of-Trend Results in Ongoing Stability Data
The authors discuss three methods for identification of out-of-trend (OOT) results and further compare the z-score method and the tolerance interval in OOT analysis for stability studies.

Pharmaceutical Technology
Volume 37, Issue 6, pp. 46-51,59


The pharmaceutical industry still lacks having a proper guideline for the identification of present OOT results among ongoing stability data. As a result, many pharmaceutical companies are not harmonized in the way they conduct this type of analysis.

In this study, three methods for identification of OOT results in ongoing stability data were proposed: the regression-control-chart method, the by-time-point method, and the slope-control-chart method. To obtain more accurate identification of existing OOT results, simultaneous use of all three methods is advised, which will result in getting a visual image of the results of the analyzed batches. The use of the z-score method for defining the limits for the OOT results is preferred. Lastly, the study highlighted the necessity of issuing a regulatory confirmed guideline for identification of OOT results within ongoing stability data.

Adrijana Torbovska* is an analyst in the Quality Control Department of ReplekPharm, Kozle 188, 1000 Skopje, Macedonia,
Suzana Trajkovic-Jolevska, PhD, is a professor in the Drug Quality Control Department, Faculty of Pharmacy, Ss Cyril and Methodius University, Skopje, Macedonia.

* To whom all correspondence should be addressed.


1. MHRA, Guidance for Out Of Secification Investigation, online presentation, (2010),, accessed May 13, 2013.

2. FDA, Guidance for Industry: Investigating Out-Of-Specification (OOS) Test Results for Pharmaceutical Production (Rockville, MD, 2006).

3. PhRMA CMC Statistics and Stability Expert Teams, Pharm. Technol. 27 (4), 38-52 (2003).

4. ICH, Q1A (R2) Stability Testing of New Drug Substances and Products (Feb. 2003).

5. P.Rowe, Essential Statistics for the Pharmaceutical Sciences (John Wiley & Sons, West Sussex, UK, 2007), pp. 169-194.

6. W.W. Daniel, Biostatistics- A Foundation for Analysis in the Health Sciences (John Wiley & Sons, Hoboken, NJ, 9th ed., 2009), pp. 93-131, 215-304, and 409-484.

7. S. Bolton and C. Bon, Pharmaceutical Statistics–Practical and Clinical Applications (Marcel Dekker Inc., Monticello, NY, Vol. 135, 4th ed., 2004), pp. 96-150.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here